Detalhe da pesquisa
1.
Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
Acta Pharmacol Sin
; 45(6): 1264-1275, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438582
2.
Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling.
Clin Respir J
; 12(12): 2642-2652, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30307719
3.
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway.
Biologics
; 12: 75-86, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30154647